TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03736304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKI alert
Description: An AKI alert will send to the doctor in charge. The team of nephrologists would give suggestions if the doctor in charge need a renal consultation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Patients will receive standard clinical care by the doctor in charge.
Study: NCT04451772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Film-coated tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Film-coated tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Film-coated tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Film-coated tablet; Oral
Study: NCT01792232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allergen
Description: Subject specific allergen is placed in the lungs on day 1 of each triad

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allergen
Description: Subject specific allergen is placed in the lungs on day 1 of each triad

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline will be placed in the lung on day 1 of each triad

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline will be placed in the lung on day 1 of each triad
Study: NCT00712920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.15% azelastine hydrochloride
Description: 0.15% azelastine hydrochloride 1644 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% azelastine hydrochloride
Description: 0.1% azelastine hydrochloride 1096 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00919672

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral nerve stimulation
Description: The stimulation is set individually to provide the best possible stimulation for each individual person. This setting is found before the study starts and will not be altered during the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral nerve stimulation
Description: The stimulation is set individually to provide the best possible stimulation for each individual person. This setting is found before the study starts and will not be altered during the study.
Study: NCT02199496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stelara (ustekinumab)
Description: * In the single-phase part of the study, subjects receive a single dose of Stelara (ustekinumab) 270 mg subcutaneously on Day 0 study visit.~* In the multi-phase part of the study, subjects receive single dose of Stelara (ustekinumab) 270 mg subcutaneously on Day 0 study visit with follow up dose of Stelara (ustekinumab) 90 mg subcutaneously at Week 8, Week 16, Week 24, Week 32 and Week 40

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stelara (ustekinumab)
Description: * In the single-phase part of the study, subjects receive a single dose of Stelara (ustekinumab) 270 mg subcutaneously on Day 0 study visit.~* In the multi-phase part of the study, subjects receive single dose of Stelara (ustekinumab) 270 mg subcutaneously on Day 0 study visit with follow up dose of Stelara (ustekinumab) 90 mg subcutaneously at Week 8, Week 16, Week 24, Week 32 and Week 40
Study: NCT03921983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation
Description: short term O2 supplementation during 1 hour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen supplementation
Description: short term O2 supplementation during 1 hour
Study: NCT00513799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin ointment
Description: Add a small amount of Mupirocin to the cotton end of a swab. Swab in inner nostril, then repeat in other nostril using new cotton swab with ointment. Twice daily treatment for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin ointment
Description: Add a small amount of Mupirocin to the cotton end of a swab. Swab in inner nostril, then repeat in other nostril using new cotton swab with ointment. Twice daily treatment for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin ointment
Description: Add a small amount of Mupirocin to the cotton end of a swab. Swab in inner nostril, then repeat in other nostril using new cotton swab with ointment. Twice daily treatment for 5 days.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine showers
Description: Apply Clorhexidine wash to entire body once daily for 5 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bleach baths (dilute)
Description: Pour 2 ounces of bleach into water-filled bath tub. Soak in bath for 15 minutes. Apply once daily for 5 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive education on personal hygiene
Description: Repeat hygiene methods for 5 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive education on personal hygiene
Description: Repeat hygiene methods for 5 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive education on personal hygiene
Description: Repeat hygiene methods for 5 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive education on personal hygiene
Description: Repeat hygiene methods for 5 days.
Study: NCT05306704

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo Oil
Description: participants will receive placebo(olive oil) orally in all visits from visit 1 to visit 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25-Hydroxyvitamin D
Description: Participants will receive vitamin D (100000IU) orally during all visits i.e. from visit-1 to visit-4
Study: NCT04650620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plenhyage® thin
Description: 0.75%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plenhyage® medium
Description: 2%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plenhyage® strong
Description: 2.5%
Study: NCT05173311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention arm
Description: The intervention arm groups were instructed to use the Mole's Veggie Adventures mobile application for 3-4 weeks.
Study: NCT04139135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: neoadjuvant treatment phase：HLX10（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：HLX10（4.5mg/kg/3w IV）

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: neoadjuvant treatment phase：placebos（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：SOX
Study: NCT02419950

Intervention type: DEVICE
Intervention: Fixation of mesh in TEP
Description: An endoscopic operative technique were mesh for preperitonelal placement in patients with inguinal hernias can be fixated in Place or left without fixation

Intervention type: DEVICE
Intervention: Fixation of mesh in TEP
Description: An endoscopic operative technique were mesh for preperitonelal placement in patients with inguinal hernias can be fixated in Place or left without fixation
Study: NCT00855608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: intravitreal adalimumab injection 0.03 ml in volume (1.5mg) one dose to one eye
Study: NCT01147835

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chinese Licorice Root
Description: Chinese Licorice Root lollipops are given to the subjects in the study group to ingest twice daily for 10 days. Then the subjects must wait 3 months, and then again ingest the lollipops twice daily for 10 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chinese Licorice Root
Description: Chinese Licorice Root lollipops are given to the subjects in the study group to ingest twice daily for 10 days. Then the subjects must wait 3 months, and then again ingest the lollipops twice daily for 10 days.
Study: NCT04502277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole Powder
Description: The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Diflucan 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole Powder
Description: The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Diflucan 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
Study: NCT00413803

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 4-hour thrice weekly in center hemodialysis
Description: conventional hemodialysis
Study: NCT01622309

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: eggplant meal
Description: 13 g meal of eggplant/day, being 6,5 g in breakfast and 6,5g in dinner
Study: NCT00413803

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 8-hour thrice weekly in center hemodialysis
Description: long dialysis
Study: NCT02921165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: analgesic mouth rinses (dissolved Aspirin)
Description: Group 1 and Group 2 patients will be prescribed analgesic mouth rinses (dissolved Aspirin) twice daily along with the standard prescription of analgesics and antibiotics.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: analgesic mouth rinses (dissolved Aspirin)
Description: Group 1 and Group 2 patients will be prescribed analgesic mouth rinses (dissolved Aspirin) twice daily along with the standard prescription of analgesics and antibiotics.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline rinses.
Description: Non Hypertensive patients will be prescribed normal saline rinses twice daily along with the standard prescription of analgesics and antibiotics.
Study: NCT01513499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Intranasal oxytocin 24 IU single-dose administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal Placebo single-dose administration
Study: NCT02640079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Study: NCT01056276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Treatment: 80 mg/m2 via intravenous (IV) Days 1 and 2; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2 IV Days 1, 8, 15; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.~Maintenance: 1.3 mg/m2 IV or SQ Days 1, 15
Study: NCT01622309

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cassava meal
Description: 13g cassava meal/day,being 6,5 g in breakfast and 6,5g in dinner
Study: NCT01056276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg orally (PO) Days 1, 2, 8, 9, 15, 16 every 28-days for 8 cycles or 2 cycles beyond confirmed complete response, Maintenance: 20 mg PO Days 1, 15
Study: NCT02363088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neutral text message reminder
Description: Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Messenger text message reminder
Description: \<GP NAME\>: Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Messenger text message reminder
Description: \<GP NAME\>: Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Norms A reminder
Description: Last year in Hillingdon 7 out of 10 women took part in cervical screening. Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Norms B reminder
Description: Last year 12000 women in Hillingdon took part in cervical screening. Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>

Intervention type: OTHER
Group type: OTHER
Intervention: Framed Gain text reminder
Description: Cervical cancer screening saves 4500 lives in England every year. Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Framed Loss text reminder
Description: Failing to attend cervical screening could lead to 4500 avoidable deaths in England each year. Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>
Study: NCT01285544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin (Lipinon)
Description: treatment of dyslipidemia administration : PO, qod

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin (Lipitor)
Description: treatment of dyslipidemia administration : PO, qod
Study: NCT01852903

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium ascorbate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ascorbic acid
Study: NCT02087007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: 100mg oral tablets bid during 2 weeks after dosing of 50mg oral tablets bid during 2 weeks
Study: NCT01852903

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00937950

Intervention type: OTHER
Group type: OTHER
Intervention: Gynaecological follow-up
Description: Subjects received a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to four years in this gynaecological follow-up study (HPV-052 EXT 008). No vaccine was administered in this extension study. Subjects received 3 doses of Cervarix/Havrix vaccine, administered intramuscularly, according to a 0, 1, 6-month vaccination schedule in the HPV-008 (NCT00122681) primary study.
Study: NCT03195556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound exposure of Definity microbubbles infused over 10 min. Ultrasound administered at 1.3 MHz, mechanical index of 1.3, and pulsing interval of 10 s.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound exposure of Definity microbubbles infused over 10 min. Ultrasound administered at 1.3 MHz, mechanical index of 1.3, and pulsing interval of 10 s.
Study: NCT02087007

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100mg oral placebo tablets bid during 2 weeks after dosing of 50mg oral placebo tablets bid during 2 weeks
Study: NCT02529553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3076226
Description: Administered IV
Study: NCT03723824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: grazoprevir 100 mg/ elbasvir 50 mg, Zepatier®
Description: grazoprevir 100 mg/ elbasvir 50 mg (Zepatier®, MSD) once daily for 12 weeks
Study: NCT02821845

Intervention type: BEHAVIORAL
Intervention: Untrained and Trained SCI Hip or Knee
Description: Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of hip control or knee control, members of this group will be trained at slow to moderate gait speeds,
Study: NCT01458977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada® (300 mg tenofovir disoproxil fumarato/200 mg emtricitabine)
Description: TDF/FTC 300/200mg daily during 3 months + Placebo during 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo during 3 months + TDF/FTC 300/200mg daily during 3 months + Placebo during 3 months
Study: NCT02215018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 TA solution
Study: NCT00724776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albinterferon alfa 2b
Description: recombinant human albumin-interferon alfa fusion protein, 600-1800mcg single dose by S.C. on Day 0
Study: NCT05098561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Treatment
Description: The nurse will set up the appropriate music genre for the each music treatment patient, based on patient's preference obtained from the pre-operative questionnaire, by using the bedside computer and using Pandora, the internet music streaming service.
Study: NCT00250588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving skills training
Description: See description in Results

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma care coordination
Description: See description in Results

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma care coordination
Description: See description in Results

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual clinical care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual clinical care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual clinical care
Study: NCT04489368

Intervention type: RADIATION
Intervention: Neo-Adjuvant Radiotherapy
Description: Neo-Adjuvant Radiotherapy via any technique, delivered concurrently with Neo-Adjuvant Chemotherapy.

Intervention type: DRUG
Intervention: Neo-Adjuvant Chemotherapy
Description: Neo-Adjuvant Chemotherapy, delivered concurrently with Neo-Adjuvant Radiotherapy.

Intervention type: PROCEDURE
Intervention: Esophagectomy
Description: Esophagectomy, performed 4-6 weeks after completion of Neo-Adjuvant Concurrent ChemoRadiation
Study: NCT02191501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pyloric restriction
Description: The Apollo Overstitch Suturing Device is FDA approved for suturing in the gastrointestinal tract.~However, the suturing device has never been used for suturing the pylorus in humans before. This procedure is not standard medical care. The safety and effectiveness of this procedure are being tested.
Study: NCT02215018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 TA tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Study: NCT00435942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relay Thoracic Stent-Graft
Description: implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Repair
Description: Open surgery
Study: NCT02908230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Care
Description: 8-week (nutrition, physical activity, and mental health) summer curriculum/program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: 8-week (nutrition and physical activity) summer curriculum/program

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Active Control
Description: 8-week (non-nutrition, physical activity or mental health) summer curriculum/program
Study: NCT02378181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education Toolkit
Description: An existing evidence-based toolkit intervention will be adapted and redesigned by a patient and provider team into an engaging, narrative graphic novel curriculum. The proven behavioral interventions will be augmented with health education material focused on MAT and HIV risk reduction. Together, these materials will comprise the Health Education Toolkit. The Health Education Toolkit (TK) will employ a shared decision making model to encourage 1) increased recovery engagement by patients, and 2) patient engagement in deciding whether to initiate and adhere to MAT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Treatment-as-usual will consist of the same number of counseling sessions as the experimental TK condition, but the counselors working with patients in this condition will not be equipped with the TK materials.
Study: NCT02215018

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Study: NCT04034472

Intervention type: OTHER
Group type: OTHER
Intervention: Interdisciplinary intervention in obesity
Description: Interdisciplinary weight loss intervention associate to the use of digital technology to treat obesity and related disorders
Study: NCT00412620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-925

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03698149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMT/Blackrock Combination Device
Description: PMT Subdural Cortical Electrodes/Blackrock NeuroPort Array and NeuroPort System
Study: NCT00815074

Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study: NCT03719664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuvirtide
Description: Intravenous infusion of Albuvirtide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuvirtide
Description: Intravenous infusion of Albuvirtide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuvirtide
Description: Intravenous infusion of Albuvirtide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuvirtide
Description: Intravenous infusion of Albuvirtide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuvirtide
Description: Intravenous infusion of Albuvirtide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous infusion of 3BNC117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous infusion of 3BNC117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous infusion of 3BNC117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous infusion of 3BNC117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous infusion of 3BNC117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baseline ART
Description: Subjects continuing on baseline ART
Study: NCT02784639

Intervention type: OTHER
Group type: OTHER
Intervention: Plasma Analysis of circulating cell free DNA
Study: NCT03719664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baseline ART
Description: Subjects continuing on baseline ART